Bone Marrow-Derived Stem Cells in Treating Endometrial Dysfunction

Regenerative Medicine is one of the most promising areas of the Translational Medicine today. This new concept is based on the ability to replace and reconstruct human tissues or organs with the aim to restore physiological function.

Endometrial regeneration is mediated by the existence of tissue specific resident stem cells identified during the last years (Cervelló et al., PLoS One 2010; 2011; PLoS One, Masuda et al., PLoS One 2010). The important key role of the bone marrow, in the reconstitution of the human endometrium, like a reservoir of stem and progenitor cells has been previously suggested (Cervelló et al., PLoS One 2012). Cell therapy using autologous Human Bone Marrow-Derived Stem Cells (hBMDSCs) is used for several diseases in all the human body including endometrial pathologies. Asherman´s Syndrome (AS) causes reproductive consequences including infertility, amenorrhea and recurrent miscarriage. Here, we present an autologous cell therapy using CD133+ bone marrow derived stem cells (BMDSc) in 11 patients with refractory AS and 5 with EA (Santamaria et al., Hum Reprod 2016). In the first 3 months, autologous cell therapy, using CD133+ BMDSCs, increased the volume and duration of menses as well as the thickness and angiogenesis processes of the endometrium while decreasing intrauterine adhesion scores.

Santamaria X, Cabanillas S, Cervelló I, Arbona C, Raga F, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman`s syndrome and endometrial atrophy: a pilot cohort study. Hum Reprod. 2016 May;31(5):1087-96. PubMed PMID: 27005892.